Menu
NEUROINNOVATECH’s mission is to develop cutting-edge novel drugs to improve treatment outcomes for CNS disorders, fostering better physical health, cognition, and social functioning for patients.
Central nervous system (CNS) disorders encompass a broad range of conditions that affect the brain and spinal cord. NEUROINNOVATECH’s innovative therapeutic products aims to deliver innovative CNS drugs with a strong and competitive profile against other marketed CNS products.
OCD is a mental health disorder characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors or mental rituals (compulsions). Individuals with OCD may feel driven to perform these rituals to alleviate distress or prevent perceived harm, despite recognizing that the thoughts or behaviors are excessive or irrational.
Parkinson’s disease is a progressive neurological disorder that affects movement. It is characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Parkinson’s disease results from the loss of dopamine-producing neurons in the brain, particularly in the substantia nigra region.
Epilepsy is a neurological disorder characterized by recurrent seizures, which are sudden, uncontrolled electrical disturbances in the brain. While epilepsy is not rare, there are various rare forms of epilepsy that may have distinct genetic or structural causes, leading to unique seizure types and clinical presentations.
PTSD is a mental health condition that can develop after experiencing or witnessing a traumatic event. Symptoms may include flashbacks, nightmares, hypervigilance, avoidance of trauma-related stimuli, negative changes in mood and cognition, and emotional reactivity. PTSD can significantly impact an individual’s daily functioning and quality of life.
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It can result from conditions such as diabetes, multiple sclerosis, stroke, or traumatic injuries to the nervous system. Neuropathic pain is often described as burning, shooting, or electric shock-like sensations and can be challenging to manage with conventional pain medications.
NEUROINNOVATECH is committed to in-license and develop novel drugs designed to enhance efficacy in treating CNS symptoms, improve physical health, cognition, and social functioning, thereby enhancing overall quality of life for patients. Additionally, our novel drugs aim to improve financial independence and alleviate the burden on caregivers who provide support to those affected by CNS disorders.
Establish strategic partnership with a well-established drug discover, biotech and pharma companies that possesses strong proprietary technology.
Drug formulation development and pre-clinical tests.
Generate new intellectual property (IP) rights.
Commence the initial clinical Proof of Concept (POC) study.
The anticipated timeline for advancing the development project for CNS disorder treatment and establish the global IP rights is approx. 30 months, starting in 2024.
Obsessive-Compulsive Disorder (OCD): OCD affects approximately 1-3% of the global population (80-240 million people).
Epilepsy: Globally it’s estimated that around 50 million people have epilepsy.
Parkinson’s Disease Dementia: The prevalence of Parkinson’s disease is estimated to be around 1-2% in people over 60 (80-160 million people), with approx. half of those suffering from Parkinson’s disease developing Parkinson’s disease dementia.
Post-Traumatic Stress Disorder (PTSD): In the general population, the lifetime prevalence of PTSD is estimated to be around 7-8% (560-650 million people).
Neuropathic Pain: The estimated incidence, is around 7-10% of the global population (566-810 million people).